Understand the source comparison
TB-4 Per Day Daily Dose: Protocol Comparison by Research Application
Acute Soft Tissue Injury 5–8mg Twice weekly (3–4 days apart) 2–5mg Once weekly 12–16 weeks Transition to maintenance at week 6 when granulation tissue forms Chronic Tendon/Ligament Repair 8–10mg Twice weekly 5mg 16–24 weeks Extended loading phase (8–10 weeks)
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Acute Soft Tissue Injury
- 5–8mg
- Twice weekly (3–4 days apart)
- 2–5mg
- Once weekly
- 12–16 weeks
- Transition to maintenance at week 6 when granulation tissue forms
- Chronic Tendon/Ligament Repair
- 8–10mg
- Twice weekly
- 5mg
- 16–24 weeks
- Extended loading phase (8–10 weeks) due to slower collagen remodelling timelines
- Dermal Wound Healing
- 2–3mg
- 8–12 weeks
- Re-epithelialisation typically complete by week 4; early transition to maintenance
- Cardiac Tissue Repair (Post-Ischaemia)
- 20+ weeks
- Angiogenesis timelines extend beyond typical wound healing; higher maintenance doses
- Neurological Tissue Models
- 3–5mg
- 16–20 weeks
- Axonal regeneration and remyelination occur over extended timelines
- This table shows that TB-4 per day daily dose protocols vary significantly by tissue type and repair phase. Cardiac and neurological models require longer loading phases and higher maintenance doses due to slower intrinsic repair kinetics. Dermal models achieve structural repair faster, allowing earlier dose reduction. The key variable isn't total weekly dose. It's administration frequency during the loading phase and the transition timing to maintenance.